#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Pleomorphic leiomyosarcoma Fragile X syndrome Ewing's sarcoma Von Hippel-Lindau disease Immune-mediated myasthenia gravis Glycogen storage disease type II Dupuytren's contracture Kaposi's sarcoma Pyoderma gangrenosum Familial haemophagocytic lymphohistiocytosis Wiskott-Aldrich syndrome Biliary neoplasm Complex regional pain syndrome Pemphigoid Chronic myeloid leukaemia (in remission) More trials…

    Learn about Rare Diseases

    Rhabdomyosarcoma – Diagnostics Congenital hypotransferrinaemia KBG syndrome – Trials in Disease Activated PI3 kinase delta syndrome Loeys-Dietz syndrome – Basic Information Gaucher’s disease type III – Treatment Myelodysplastic syndrome Haemophilia A with anti factor VIII – Diagnostics Ocular melanoma – Life with Disease Basal cell naevus syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tiragolumab Caspofungin Ramucirumab Lenacapavir Cannabis Sativa Flower Pehero TRIGLYCERIDES MEDIUM CHAIN Rbd5044 Sodium Erenumab Casirivimab Roxadustat Silibinin Meropenem Trihydrate Posdinemab VALACICLOVIR HYDROCHLORIDE Ceritinib Alemtuzumab Zilucoplan Sodium Acemetacin Micafungin More therapies…

    Learn about Your Condition

    Renal injury Relapsing multiple sclerosis Spinal muscular atrophy Rett syndrome Medulloblastoma Choreoathetosis Inborn error of metabolism Colon cancer stage II Double hit lymphoma Retinal vein occlusion Portal hypertension Malignant melanoma stage IV Ankylosing spondylitis Obsessive-compulsive disorder Breast cancer stage III More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Narcolepsy

  • Study on the Long-term Safety of TAK-861 for Patients with Narcolepsy Type 1

    Recruiting

    4 1 1
    Investigated Drugs:
    • N-{(2S,3R)-4,4-Difluoro-1-(2-Hydroxy-2-Methylpropanoyl)-2-[(2,3′,5′-Trifluoro[1,1′-Biphenyl]-3-Yl)Methyl]Pyrrolidin-3-Yl}Ethanesulfonamide
    Austria Belgium Finland France Germany Italy +5

  • Efficacy and Safety of ALKS 2680 and Alixorexton in Adults with Narcolepsy Type 1

    Not yet recruiting

    3 1
    Investigated Drugs:
    • Alks 2680
    Austria Belgium Finland France Germany Italy +5

  • Efficacy and Safety of E2086 in Adults with Narcolepsy: A Randomized, Double‑Blind, Placebo‑Controlled Trial

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Narcolepsy
    Belgium Germany Italy Spain

  • A Randomized Double‑Blind Placebo‑Controlled Study of TAK‑360 in Adults with Narcolepsy with Cataplexy (Type 1)

    Not yet recruiting

    2 1
    France Italy Spain

  • Study on TAK-861 for Treating Narcolepsy with Cataplexy in Patients

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Narcolepsy
    Investigated Drugs:
    • N-{(2S,3R)-4,4-Difluoro-1-(2-Hydroxy-2-Methylpropanoyl)-2-[(2,3′,5′-Trifluoro[1,1′-Biphenyl]-3-Yl)Methyl]Pyrrolidin-3-Yl}Ethanesulfonamide
    Austria Belgium Czechia Denmark Finland France +5

  • A study testing the safety and how the body processes TAK-861 in children and teenagers aged 6 to 17 years with narcolepsy type 1

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Narcolepsy
    Investigated Drugs:
    • N-{(2S,3R)-4,4-Difluoro-1-(2-Hydroxy-2-Methylpropanoyl)-2-[(2,3′,5′-Trifluoro[1,1′-Biphenyl]-3-Yl)Methyl]Pyrrolidin-3-Yl}Ethanesulfonamide
    Italy
Previous Page
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!